OGN News and Press, Organon & Co. From 01/12/24

2024-01-12 08:00:02 ET Piper Sandler analyst issues OVERWEIGHT recommendation for OGN on January 12, 2024 08:26AM ET. The previous analyst recommendation was Overweight. OGN was trading at $16.83 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-01-11 10:50:00 ET Summary Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. The Miller Income Strategy returned 11.07% net of fees in the fourth quarter of 2023 versus a 7.04% return for its benchmark....

2024-01-10 10:04:45 ET More on Dare Bioscience, Organon, etc. Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90%...

Despite being the most common vaginal condition, 1 BV symptoms are often mistaken for a yeast infection 2 Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by p...

2024-01-09 22:55:25 ET Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference Call January 9, 2024 16:30 ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Christophe...

2024-01-08 08:02:40 ET More on Organon Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Organon: It's Darkest Before The Dawn EU suggests label update to flag brain-related...

Regular dividend to remain primary capital allocation priority For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on November 2, 2023 For full year 2023 the company expects free cash flow before one-time spin-related costs to ...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-03 08:10:00 ET Summary Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in the fertility busi...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...